

09/618,361

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,737,408 B1
DATED : May 18, 2004
INVENTOR(S) : Balasubramaniam et al.

Page 1 of 5

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page,

Item [56], **References Cited**, OTHER PUBLICATIONS,

"A." reference, "Balasubramaniam" should be -- Balasubramaniam --.

"M. Heilig" reference, "Dept. of Psychiatry and Neurochemistry, University of Lund, Lund, Sweden, Mar. 17, 1990, pp. 95-114" should be -- Acta Psychiatr. Scand, vol. 82, 1990, 95-114 --.

"Shin-ichi" reference, "Y.induced" should be -- Y-induced --.

"William M. Pardridge" reference, "vol. 126, 1990" should be -- vol. 126, No. 2, 1990 --.

"Thue" reference, "Annuals" should be -- Ann.--.

Column 1,

Line 41, "dope minergic" should be -- dopaminergic --.

Line 48, "with the actions other drugs" should be -- with the actions of other drugs --.

Line 65, "Amsterd in -New York-Oxford" should be -- Amsterdam-New York-Oxford --.

Column 2,

Line 32, "A. Fournier" should be -- A. Fournier --.

Line 40, "Humana Press, Inc ," should be -- Humana Press, Inc., --.

Line 48, "Y.-S. Zhang" should be -- Y. S. Zhang --.

Column 3,

Line 9, "H. . Thogersen" should be -- H. Thogersen, --.

Column 4,

Line 12, "J. D. Rosarnond" should be -- J. D. Rosamond --.

Line 61, "CaMe-Trp, CaMe-Gin" should be -- CaMe-Trp, CaMe-Gln --.

Column 5,

Line 7, "des- arboxylic-Tyr" should be -- des-carboxylic-Tyr --.

Line 10, "(where R3" should be -- where R3 --.

Line 11, "independently, is" should be -- independently are --.

Line 12, "(e-g-, phenyl)" should be -- (e.g., phenyl) --.

Column 6,

Line 18, "(N-a-indole-3-acetyl-" should be -- (N- α -indole-3-acetyl- --

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,737,408 B1
DATED : May 18, 2004
INVENTOR(S) : Balasubramaniam et al.

Page 2 of 5

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 7,

Line 4, "(where R3" should be -- where R3 --.
Line 5, "independently, is" should be -- independently, are --.
Line 49, "formula I-III)" should be -- formula (I-III) --.
Line 53, "the invention features" should be -- the invention featuring --.

Column 8,

Line 20, "in the form a pill" should be -- in the form of a pill --.
Line 25, "administration biodegradable" should be -- administration is biodegradable --.
Line 44, "R is -CH3" and should read -- R is CH₃ --.

Column 9,

Line 3, "Phenytalanine" should be -- Phenylalanine --.
Line 11, "(8-aminooctanoic acid:" should be -- (8-aminooctanoic acid) --.
Line 28, "arboxylic acid" should be -- carboxylic acid --.
Line 34, "Citrutine" should be -- Citruline --.
Line 36, "diaminopimelicacid" should be -- diaminopimelic acid --.
Line 63, "The terms "CI-C-18-alkyl" as used herein refer to" should be -- The term "C1-C-18-alkyl" as used herein refers to --.

Column 10,

Line 9, "C1-C4alkyl" should be -- C1-C4-alkyl --.
Line 22, "-OSO3H" should be -- OSO₃H --.

Column 11,

Line 16, "1000 mg a day and more usually" should be -- 1000 mg a day and more, usually --.
Line 24, "administer.a" should be -- administer a --.
Line 25, "particular compounds," should be -- particular compound, --.
Line 40, "ex ample" should be -- example --.
Line 53, "tablets , or" should be -- tablets, or --.
Line 62 reads "suspension provide the" and should read -- suspension provides the --.

Column 12,

Line 2, "a hexitol or a hexitol anhydrides," should be -- a hexitol or hexitol anhydrides --.
Line 54, "typically" should be -- typical --.
Line 54, "enhances" should be -- enhancers --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,737,408 B1
DATED : May 18, 2004
INVENTOR(S) : Balasubramaniam et al.

Page 3 of 5

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 14,

Line 12, "lipogencis" should be -- lipogenesis --.

Column 15,

Line 45, "Bzl:" should be -- Bzl; --.

Lines 59-60, "program" should be -- programs --.

Column 16,

Line 12, "eralier" should be -- earlier --.

Line 16, "a-amino" should be -- α -amino --.

Line 18, "NaBH₃CN" should be -- NaBH₃CN --.

Line 27, "toBOP/HOBT" should be -- to BOP/HOBT --.

Line 46, "hydrolyxed" should be - hydrolyzed --.

Lines 47 and 49, "110_C" should be -- 110°C --.

Column 17,

Line 19, "fuictionalization" should be -- functionalization --.

Line 62, "citirc" should be -- citric --.

Line 63, "as wells as" should be -- as well as --.

Line 66, "may, if desired, may be" should be -- may, if desired, be --.

Column 18,

Line 17, "Ac-Trp-Arg-Tyr-(Y)-NH" should be -- Ac-Trp-Arg-Tyr-(Ψ)-NH --.

Line 29, "R=" should be -- where R= --.

Line 31, add -- = 12. R-CO-Trp-Arg-Tyr-NH₂ --.

Line 38, delete "R=".

Line 41, delete "where R=."

Line 42, delete "12. R-CO-Trp-Arg-Tyr-NH₂."

Line 52, "[Cys³⁴]" should be -- [Cys₃₄] --.

Line 55, "Arg((Pr)₂)" should be -- Arg(Pr)₂ --.

Line 58, "N-a-Indole-3" should be -- N- α -Indole-3 --.

Line 59, "Ac-T ec-Arg-Tyr" should be -- Ac-Tcc-Arg-Tyr --.

Line 60, "Ac-pro-Arg" should be -- Ac-Pro-Arg --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,737,408 B1
DATED : May 18, 2004
INVENTOR(S) : Balasubramaniam et al.

Page 4 of 5

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 19,

Line 1, "38. Ac-[-Trp-Arg-Tyr-]₂ -NH" should be -- 38. Ac-[-Trp-Arg-Tyr-]₂ -NH (SEQ ID NO: 6) --.

Line 7, "Cyclo[-Trp-Arg-Nva-Arg Tyr-]".

Line 14, "Cyclo[-Trp-Arg-Tyr-Trp-Arg-Tyr-]" should be
-- Cyclo[-Trp-Arg-Tyr-Trp-Arg-Tyr-] (SEQ ID NO: 7) --.

Column 20,

Line 9, "24_C" should be -- 24°C --.

Line 20, "Adenlyate" should be -- Adenylate --.

Line 21, "mebranes" should be -- membranes --.

Line 23, "MgCl2" should be -- MgCl₂ --.

Line 27, "isopretemol" should be -- isopreternol --.

Line 29, "35_C" should be -- 35°C --.

Line 32, "adenlyate" should be -- adenylate --.

Line 44, "Spraque" should be -- Sprague --.

Column 21,

Line 5, "-2_C" should be -- -2°C --.

Line 25, "Tyr-NH" should be -- -Tyr-NH --.

Line 33, "N6di-Boc-Pim" should be -- N6-di-Boc-Pim --.

Line 35, "DEA" should be -- DIEA --.

Line 60, "MOD RES" should be -- MOD_RES --.

Column 22,

Line 4, "intrahypoythala nic" should be -- intrahypothalamic --.

Line 6, "(45 mg.kg)" should be -- 45 mg/kg --.

Line 7, "perifomical" should be -- perifomical --.

Line 8, "athe the" should be -- at the --.

Line 12, "arc divided" should be -- are divided --.

Line 14, "(N-a-indole-3-" should be -- (N- α -indole-3 --.

Line 20, "arc shown" should be -- are shown --.

Column 23,

Line 8, "<221> NAME/KEY: MOD RES" should be -- <221> NAME/KEY:
MOD_RES --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,737,408 B1
DATED : May 18, 2004
INVENTOR(S) : Balasubramaniam et al.

Page 5 of 5


It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 26,

Line 4, "physical" should be -- physiological --.

Signed and Sealed this

Third Day of May, 2005

A handwritten signature in black ink, reading "Jon W. Dudas". The signature is stylized with a large, looping initial "J" and a cursive "Dudas".

JON W. DUDAS
Director of the United States Patent and Trademark Office